Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)
This study has been withdrawn prior to enrollment.
(Award was ended by NIH for parent study)
Massachusetts General Hospital
National Heart, Lung, and Blood Institute (NHLBI)
New England Research Institutes
Information provided by (Responsible Party):
Ravi Thadhani, Massachusetts General Hospital
First received: October 8, 2013
Last updated: September 9, 2017
Last verified: September 2017
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||May 2018|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|